Ruxolitinib

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 3839 publications

Efficacy and Safety of Topical 1.5% Ruxolitinib for Chronic Hand Eczema in Real‑World Practice.

Efficacy and Safety of Topical 1.5% Ruxolitinib for Chronic Hand Eczema in Real‑World Practice.

Journal: Journal of cutaneous medicine and surgery
Published: June 23, 2026

Current outlook on the use of biological agents to improve outcomes in adult secondary hemophagocytic lymphohistiocytosis.

Current outlook on the use of biological agents to improve outcomes in adult secondary hemophagocytic lymphohistiocytosis.

Journal: Expert opinion on biological therapy
Published: June 23, 2026

Targeting the cytokine storm: new therapies in the treatment of paediatric haemophagocytic lymphohistiocytosis.

Targeting the cytokine storm: new therapies in the treatment of paediatric haemophagocytic lymphohistiocytosis.

Journal: Expert review of clinical immunology
Published: June 18, 2026

Disseminated Tuberculosis Mimicking Metastatic Cancer During Ruxolitinib Therapy for Polycythemia Vera: A Case Report and Literature Review.

Disseminated Tuberculosis Mimicking Metastatic Cancer During Ruxolitinib Therapy for Polycythemia Vera: A Case Report and Literature Review.

Journal: The American journal of case reports
Published: June 18, 2026

Targeting the cytokine storm: new therapies in the treatment of pediatric hemophagocytic lymphohistiocytosis.

Targeting the cytokine storm: new therapies in the treatment of pediatric hemophagocytic lymphohistiocytosis.

Journal: Expert review of clinical immunology
Published: June 18, 2026

Multiomic Analysis Reveals an IFN-driven Cellular Landscape Effectively Targeted by Ruxolitinib in Hailey-Hailey Disease.

Multiomic Analysis Reveals an IFN-driven Cellular Landscape Effectively Targeted by Ruxolitinib in Hailey-Hailey Disease.

Journal: bioRxiv : the preprint server for biology
Published: June 12, 2026

Refractory Pembrolizumab-Induced Myocarditis-Myositis-Myasthenia Gravis Overlap Syndrome With Concurrent Hepatitis and Thyroiditis in Endometrial Carcinoma: A Case Report.

Refractory Pembrolizumab-Induced Myocarditis-Myositis-Myasthenia Gravis Overlap Syndrome With Concurrent Hepatitis and Thyroiditis in Endometrial Carcinoma: A Case Report.

Journal: Cureus
Published: June 05, 2026

Delivery timing determines senomorphic efficacy: delayed local ruxolitinib restores macrophage polarization and rescues age-impaired bone repair.

Delivery timing determines senomorphic efficacy: delayed local ruxolitinib restores macrophage polarization and rescues age-impaired bone repair.

Journal: Research square
Published: June 04, 2026

Emerging topical nonsteroidal therapies in pediatric dermatology: atopic dermatitis, psoriasis, alopecia areata, vitiligo, and seborrheic dermatitis.

Emerging topical nonsteroidal therapies in pediatric dermatology: atopic dermatitis, psoriasis, alopecia areata, vitiligo, and seborrheic dermatitis.

Journal: Current opinion in pediatrics
Published: June 04, 2026

Distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single-center retrospective study.

Distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single-center retrospective study.

Journal: Hematology (Amsterdam, Netherlands)
Published: June 04, 2026

Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve Myelofibrosis: Phase 3 SENTRY Trial.

Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve Myelofibrosis: Phase 3 SENTRY Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 02, 2026

JAK Inhibitor-Induced Improvement of IgA Nephropathy in a Patient With Polycythemia Vera: A Case Report.

JAK Inhibitor-Induced Improvement of IgA Nephropathy in a Patient With Polycythemia Vera: A Case Report.

Journal: Kidney medicine
Published: May 29, 2026
Showing 1-12 of 3,839

Last Updated: 06/30/2026